RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
This Quarter Return
+11.17%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$3.93B
AUM Growth
+$3.93B
(-2.9%)
Cap. Flow
-$151M
Cap. Flow
% of AUM
-3.83%
Top 10 Holdings %
Top 10 Hldgs %
32.87%
Holding
120
New
16
Increased
40
Reduced
11
Closed
6
Top Buys
| 1 |
Surgery Partners
SGRY
|
$29.4M |
| 2 |
Eli Lilly
LLY
|
$26.3M |
| 3 |
Madrigal Pharmaceuticals
MDGL
|
$23.4M |
| 4 |
Viking Therapeutics
VKTX
|
$21.4M |
| 5 |
Oscar Health
OSCR
|
$20.4M |
Top Sells
Sector Composition
| 1 | Healthcare | 96.88% |
| 2 | Consumer Staples | 1.95% |
| 3 | Industrials | 0.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
MREO
51
Mereo BioPharma
MREO
$272M
| $26.9M | 0.68% | 8,142,109 +158,258 | +2% | +$522K |
|
52
Travere Therapeutics
TVTX
$1.56B
| $26.4M | 0.67% | 3,424,818 +653,372 | +24% | +$5.04M |
|
|
CERE
53
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $23.2M | 0.59% | 547,946 -2,126,299 | -80% | -$89.9M |
|
54
Disc Medicine
IRON
$2.07B
| $22.6M | 0.57% | 363,468 | – | – |
|
55
Collegium Pharmaceutical
COLL
$1.22B
| $21.8M | 0.55% | 562,000 | – | – |
|
|
56
Viking Therapeutics
VKTX
$3.04B
| $21.4M | 0.54% | +261,000 | New | +$21.4M |
|
57
Dynavax Technologies
DVAX
$1.19B
| $20.8M | 0.53% | 1,675,474 | – | – |
|
58
Zai Lab
ZLAB
$3.68B
| $20.8M | 0.53% | 1,297,123 +160,100 | +14% | +$2.56M |
|
59
MacroGenics
MGNX
$112M
| $19.2M | 0.49% | 1,305,250 +126,454 | +11% | +$1.86M |
|
60
Novo Nordisk
NVO
$251B
| $18.9M | 0.48% | +147,500 | New | +$18.9M |
|
61
Krystal Biotech
KRYS
$4.27B
| $18.5M | 0.47% | 103,969 | – | – |
|
62
BioCryst Pharmaceuticals
BCRX
$1.74B
| $17.8M | 0.45% | 3,496,256 +225,875 | +7% | +$1.15M |
|
63
Structure Therapeutics
GPCR
$1.11B
| $17.7M | 0.45% | 412,649 +125,973 | +44% | +$5.4M |
|
64
Pharvaris
PHVS
$1.39B
| $17.4M | 0.44% | +752,924 | New | +$17.4M |
|
65
Prothena Corp
PRTA
$441M
| $15.5M | 0.39% | 625,048 | – | – |
|
|
NVRO
66
DELISTED
NEVRO CORP.
NVRO
| $15.4M | 0.39% | 1,065,000 +40,000 | +4% | +$578K |
|
67
Vera Therapeutics
VERA
$1.38B
| $14.7M | 0.37% | +341,168 | New | +$14.7M |
|
68
Mersana Therapeutics
MRSN
$36.5M
| $13.6M | 0.35% | 3,046,782 | – | – |
|
69
Amicus Therapeutics
FOLD
$2.34B
| $13.6M | 0.34% | 1,152,656 +88,850 | +8% | +$1.05M |
|
70
Crinetics Pharmaceuticals
CRNX
$2.92B
| $13.5M | 0.34% | +289,400 | New | +$13.5M |
|
71
Charles River Laboratories
CRL
$8.04B
| $13.1M | 0.33% | +48,500 | New | +$13.1M |
|
72
BioMarin Pharmaceuticals
BMRN
$11.2B
| $13M | 0.33% | 148,832 | – | – |
|
73
Dyne Therapeutics
DYN
$1.92B
| $12.8M | 0.33% | +451,824 | New | +$12.8M |
|
74
Jasper Therapeutics
JSPR
$45.5M
| $11.9M | 0.3% | +404,335 | New | +$11.9M |
|
75
Compass Therapeutics
CMPX
$483M
| $10.9M | 0.28% | 5,513,788 | – | – |
|